David F. McDermott

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations

Medicine, Oncology, Pharmacotherapy +15

Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma

Ken Wyman, Michael B. Atkins, Víctor M. Prieto et al. · Cancer · 2006 · 273 citations

Medicine, Oncology, Pharmacology +10

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

Ronald M. Bukowski, Walter M. Stadler, David F. McDermott et al. · Oncology · 2010 · 41 citations

Pharmacy, Oncology, Pharmacotherapy +14

Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features

T. Logan, David F. McDermott, J. P. Dutcher et al. · Journal of Clinical Oncology · 2008 · 37 citations

Medicine, Oncology, Renal Pharmacotherapy +12

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

P. Fischer, P. Patel, M. A. Carducci et al. · Journal of Clinical Oncology · 2008 · 29 citations

Medicine, Oncology, Pharmacology +11